The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation

Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti, START-Register, Sophie Testa, Oriana Paoletti, Vittorio Pengo, Anna Falanga, Teresa Lerede, Giuliana Guazzaloca, Malattie Coagulazione, Daniela Poli, Rossella Marcucci, Antonietta Piana, Francesco Cibecchini, Lucia Ruocco, Giacomo Lucarelli, Carmelo Paparo, Giuliana Martini, Giovanni Scovoli, Salvatore Bradamante, Giuseppe Malcangi, Maria Lombardi, Antonio Insana, Andrea Toma, Pietro Barbera, Lucilla Masciocco, Pasquale Saracino, Angelo Benvenuto, Claudio Vasselli, Rosella Sangiorgio, Luciano Crippa, Simona Pedrini, Federica Bertola, Serena Rupoli, Domenico Lione, Samantha Pasca, Vanessa Roldan, Vincenza Rossi, Eugenio Bucherini, Paolo Gresele, Catello Mangione, Silvana Cicconi, Paola Casasco, Giancarlo Castaman, Alberto Tosetto, Nicola Lucio Liberato, Cesarina Bendotti, Vincenzo Oriana, Paolo Manotti, Maddalena Loredana Zighetti, Paolo Pedico, Enzo Fidone, Carla Lombardo, Mazara Del Vallo, Ornella Onorina Paci, Simona Pezzella, Mario Pezzo, Antonio Ciampa, Gabriella Molini, Aurora Ciardiello, Marco Marietta, Anna Turrini, Doris Barcellona, Gualtiero Palareti, Nicola Magrini, Francesco Marongiu, Vittorio Pengo, Daniela Poli, Armando Tripodi, Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo, Armando Tripodi, Nicola Magrini, Francesco Marongiu, Gualtiero Palareti, START-Register, Sophie Testa, Oriana Paoletti, Vittorio Pengo, Anna Falanga, Teresa Lerede, Giuliana Guazzaloca, Malattie Coagulazione, Daniela Poli, Rossella Marcucci, Antonietta Piana, Francesco Cibecchini, Lucia Ruocco, Giacomo Lucarelli, Carmelo Paparo, Giuliana Martini, Giovanni Scovoli, Salvatore Bradamante, Giuseppe Malcangi, Maria Lombardi, Antonio Insana, Andrea Toma, Pietro Barbera, Lucilla Masciocco, Pasquale Saracino, Angelo Benvenuto, Claudio Vasselli, Rosella Sangiorgio, Luciano Crippa, Simona Pedrini, Federica Bertola, Serena Rupoli, Domenico Lione, Samantha Pasca, Vanessa Roldan, Vincenza Rossi, Eugenio Bucherini, Paolo Gresele, Catello Mangione, Silvana Cicconi, Paola Casasco, Giancarlo Castaman, Alberto Tosetto, Nicola Lucio Liberato, Cesarina Bendotti, Vincenzo Oriana, Paolo Manotti, Maddalena Loredana Zighetti, Paolo Pedico, Enzo Fidone, Carla Lombardo, Mazara Del Vallo, Ornella Onorina Paci, Simona Pezzella, Mario Pezzo, Antonio Ciampa, Gabriella Molini, Aurora Ciardiello, Marco Marietta, Anna Turrini, Doris Barcellona, Gualtiero Palareti, Nicola Magrini, Francesco Marongiu, Vittorio Pengo, Daniela Poli, Armando Tripodi

Abstract

START-Register--Survey on anTicoagulated pAtients RegisTer--is an independent, inception-cohort, observational, collaborative database aimed at recording prospectively the clinical history of adult patients starting anticoagulant treatment for any reason and using whatever drug. In this article we present the START-Register and give cross section baseline data focusing on non valvular atrial fibrillation (NVAF). Participants are asked to insert prospectively consecutive patients recorded as electronic file on the web-site of the registry. Required data are: demographic and clinical characteristics of patients, associated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treatment, expected therapeutic range (in cases of treatment with vitamin K antagonists -VKAs). The follow-up is carried out to record: quality of treatment (for patients on VKAs), bleeding complications, thrombotic events, and the onset of any type of associated disease. To date 5252 patients have been enrolled; 97.6% were on VKAs because direct oral anticoagulants (DOAC) have been available in Italy only recently. The median age was 74 years [interquartile range (IQR) 64-80]; males 53.7%. This analysis is focused on the 3209 (61.1%) NVAF patients. Mean CHADS2 score was 2.1 ± 1.1, CHADSVASc score was 3.1 ± 1.3;median age was 76 years (IQR 70-81); 168 patients (5.3%) had severe renal failure [Creatinine clearance (CrCl) <30 ml/min]. Moderate renal failure (CrCl 30-59 ml/min) was found in 1265 patients (39.5%). The analysis of the START-Register data shows that two-third of patients who started chronic anticoagulant treatment had NVAF, one-third of them was > 80 years with high prevalence of renal failure.

Trial registration: ClinicalTrials.gov NCT02219984.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e44S–88S. 10.1378/chest.11-2292
    1. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008; 29: 1181–1189. 10.1093/eurheartj/ehn139
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–1151. 10.1056/NEJMoa0905561
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–891. 10.1056/NEJMoa1009638
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981–992. 10.1056/NEJMoa1107039
    1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013. 369: 2093–2104. 10.1056/NEJMoa1310907
    1. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342–2352. 10.1056/NEJMoa0906598
    1. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Lensing AW, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499–2510. 10.1056/NEJMoa1007903
    1. Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297. 10.1056/NEJMoa1113572
    1. Buller HR, Decousus H, Grosso MA, Middeldorp S, Prins MH, Raskob GE, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415. 10.1056/NEJMoa1306638
    1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808. 10.1056/NEJMoa1302507
    1. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709–718. 10.1056/NEJMoa1113697
    1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699–708. 10.1056/NEJMoa1207541
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–266
    1. Gage BF, vanWalraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation—Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287–2292.
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263–272. 10.1378/chest.09-1584
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093–1100. 10.1378/chest.10-0134
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 236–239.
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3: 692–694
    1. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013; 8: e63479 10.1371/journal.pone.0063479
    1. Volterrani M, Iellamo F, Rosano G, Guarini P, Pusineri E, Bonassi S, et al.; SICOA (Società Italiana Cardiologia Ospedalità Accreditata) Investigators. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Int J Cardiol. 2013;168:4729–4733 10.1016/j.ijcard.2013.07.169
    1. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014; 16:6–14. 10.1093/europace/eut263

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel